Searched for
AFLIBERCEPT
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...- Zydus Lifesciences in focus after USFDA clears Ahmedabad plant, Aflibercept biosimilar launchZydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and launching ANYRA, India...
- Stocks in news: Federal Bank, Waaree Energies, ICICI Pru life, Zydus, HULIndian markets experienced a downturn on Thursday, with profit-taking and a risk-off sentiment leading to a decline. Key stocks like Federa...
- Zydus launches biosimilar for ophthalmic careZydus Lifesciences has introduced Anyra, its first indigenously developed biosimilar for the treatment of visual impairment in India. This ...
- Biocon Biologics secures market entry for Yesafili in USBiocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili...
- How is India transforming the global biopharma landscape?In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. ...
- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Biocon arm's growth formula: US rollouts & debt reductionBiocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emp...
- Biocon Biologics to raise debt of Rs 4,500 crore for Viatris PayoutBiocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...
- USFDA approves Biocon Biologics' biosimilar product to treat ophthalmology conditionsBiocon Biologics received US Food and Drug Administration (USFDA) approval for biosimilar Yesafili, a vascular endothelial growth factor in...
- Biocon Biologics settles patent issue; paves way for launch of biosimilar product in CanadaBiocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalm...
- New Group CEO is someone who understands Biocon's business synergy well: Kiran Mazumdar-Shaw"Peter, who is a veteran when it comes to the pharma and biopharma industry in terms of his global experience, also understands the Biocon ...
- Lupin, DKSH enter pact to commercials Alvotech biosimilars in PhilippinesThe biosimilars planned under this agreement include biosimilar Prolia (denosumab 60mg/ml) and Xgeva (denosumab 70 mg/ml) for treating oste...
- Shilpa Medicare arm gets NoC to conduct clinical studies for its Biosimilar AfliberceptListed pharmaceutical entity Shilpa Medicare on Monday informed the exchanges that its subsidiary Shilpa Biologicals (SBPL) has received a ...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Biocon Biologics acquires Viatris' biosimilar business for $3.34 billionBBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...
- Cipla Gulf expands partnership with Alvotech for commercialisation of four drugs in Australia, New ZealandCipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...
- Bayer's Aflibercept injection gets DCGI nod for Diabetic Macular Edema indicationDiabetic Macular Edema occurs when high blood sugar levels damage capillaries that leak fluid into the retina, resulting in swelling and bl...
- New way of preventing diabetes-associated blindness foundScientists have found a new way of preventing a blinding eye disease caused due to diabetes,by blocking a second blood vessel growth protein
- Government panel moots clinical trial waiver for two cancer drugsThe two medicines - Aflibercept and Trastuzumab emtansine - are used in treatment of metastatic colorectal cancer and metastatic breast can...
Load More
